Free Trial
NASDAQ:DARE

Dare Bioscience Q3 2026 Earnings Date & Estimates

Dare Bioscience logo
$0.66 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.64 -0.02 (-3.41%)
As of 11/13/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dare Bioscience is estimated to report Q3 2026 earnings on Monday, November 16, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Upcoming Event
Earnings Conference Call
Dare Bioscience Q3 2026
00:00 / 00:00
Live Transcript
Follow Audio

What Analysts Expect from Dare Bioscience in Q3 2026

Dare Bioscience is expected to post earnings of -$0.1267 per share on revenue of $2.04 million. In the same quarter a year earlier Dare Bioscience reported -$0.28 per share on revenue of $2.26 thousand. Dare Bioscience last reported on August 13, 2026, posting -$0.20 per share and beating the -$0.2967 consensus estimate. Dare Bioscience has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.1267
Expected Revenue
$2.04 million
Prior-Year EPS
-$0.28
Prior-Year Revenue
$2.26 thousand
Expected Revenue Growth
+89,997.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.20 (Beat by +$0.0967)
Last Quarter Revenue
$187.55 thousand
EPS Beat Rate
8 of last 8 quarters

Dare Bioscience Q3 2026 Earnings FAQ

Dare Bioscience (NASDAQ:DARE) is estimated to report Q3 2026 earnings on Monday, November 16, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Dare Bioscience's Q3 2026 earnings conference call is scheduled for Monday, November 16, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Dare Bioscience to post earnings of -$0.1267 per share for Q3 2026.

The consensus revenue estimate for Dare Bioscience is $2.04 million for Q3 2026.

Dare Bioscience Earnings Headlines

Dare Bioscience (DARE) Expected to Release Earnings on Thursday
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More Dare Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dare Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dare Bioscience and other key companies, straight to your email.

About Dare Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options.

The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.

Daré’s XACIATO, a vaginal gel for bacterial vaginosis, received U.S. Food and Drug Administration approval in 2021; the company later licensed commercialization rights to Organon. Daré is based in San Diego, California, and its leadership includes President and Chief Executive Officer Sabrina Martucci Johnson.

View Dare Bioscience Profile